Promising drugs line up for lupus treatment

Lupus drugs in late-stage development seek to address unmet needs, notably in lupus nephritis.

Expert shares tips for TNF-alpha inhibitor use in special populations

LAS VEGAS – Optimizing anti-TNF-alpha treatment starts with recognizing there is a loss of response over time, Dr. Kerdel said.

Narrowband UVB phototherapy an effective treatment for psoriasis

LAS VEGAS – Home-based UVB phototherapy is gaining in popularity and is comparable with in-office UVB in terms of accuracy and efficacy.

Serum urate level governs management of difficult-to-treat gout

LAS VEGAS – Insufficient dosing of urate lowering therapy may be a reason for perceived treatment resistance.

Take drug, patient-level factors into account for when to end antiresorptive therapy

LAS VEGAS – The agent and individual patient factors may affect the duration of treatment and the approach to resuming therapy.

Guide to the guidelines: Biologics for psoriasis

Dr. April Armstrong highlights key messages in the AAD’s guidelines for the use of biologics to treat psoriasis.

Ixekizumab psoriasis outcomes, sliced and diced

WAIKOLOA, HAWAII – The jaw-dropping NNT to achieve complete skin clearance: 2.6 patients.

What’s new with adalimumab? Plenty

WAIKOLOA, HAWAII – New information includes reassuring new long-term, real-world safety data, plus a simple early predictor of PASI 75 response.

Guselkumab tops secukinumab over 48 weeks for plaque psoriasis

CAYMAN ISLANDS – In both groups, the PASI 90 increased similarly in the first month, but was consistently higher in the guselkumab group at week 12 and after.

Topical treatments remain a good option for psoriasis

LAS VEGAS – Creams and ointments still have a role, even in the age of biologics.

Pages